Gemmus Pharma Inc.
Studies Sponsored by Gemmus, Funded by NIH-NIAID
NIA-821
Efficacy of GP1001 in an H5N1 Avian Influenza virus infection in female BALB/C mice when administered twice a day for 5 days alone and in combination with oseltamivir at 20 mg/kg/day
NIA-854
Determining the maximum tolerated dose of GP1001 in female BALB/C mice when administered twice a day for 10 days
NIA-858
Efficacy of a 1.2 mg/kg dose of GP1001 in an H5N1 Avian Influenza virus infection in female BALB/C mice when administered twice a day for 10 days alone and in combination with oseltamivir
NIA-866
Determining the maximum efficacious dose of GP1001 in an H5N1 Avian Influenza virus infection in female BALB/C mice when administered twice a day for 10 days
NIA-867
Efficacy of a 1.2 mg/kg dose of GP1001 in an H5N1 Avian Influenza virus infection in female BALB/C mice when administered twice a day for 10 days alone and in combination with oseltamivir at 1.0 mg/kg/day or 0.5 mg/kg/day
NIA-870
Effects of GP1001 administered prophylactically and therapeutically on female BALB/C mice infected with Influenza A MN/Duck/1525/81 (H5N1)